Physician profile
Eric C Troyer
NPI 1962409748
$2,507.93
in general payments reported to CMS, 2019-2025
28 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $334 · 2021: $323 · 2022: $367 · 2023: $506 · 2024: $344 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.47 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Indivior INC. | $483.57 | 2019-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $189.18 | 2023-2025 | Quviviq, Quviviq |
| Braeburn INC. | $164.04 | 2023-2025 | Brixadi |
| Orexo US, INC. | $127.80 | 2022-2025 | Zubsolv |
| Allergan, INC. | $120.94 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.15 | 2019-2023 | Xifaxan |
| Ardelyx, INC. | $72.30 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $57.42 | 2021-2024 | Airsupra |
| Gilead Sciences, INC. | $43.64 | 2025 | |
| Lilly USA, LLC | $41.14 | 2025 | Zepbound, Mounjaro |
| Halozyme INC | $35.64 | 2023 | |
| Collegium Pharmaceutical, INC. | $35.27 | 2023 | Belbuca |
| Alkermes, INC. | $33.45 | 2020-2021 | |
| Novo Nordisk INC | $33.37 | 2025 | Wegovy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $32.98 | 2020 | |
| Glaxosmithkline, LLC. | $32.10 | 2020-2023 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $27.77 | 2020 | |
| Uswm, LLC | $26.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.41 | 2022 | |
| Forte Bio-Pharma LLC | $17.93 | 2023 | Prolate, Nalocet |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.63 | 2024 | Caplyta |
| Tolmar, INC. | $16.60 | 2025 | Jatenzo |
| Pfizer INC. | $13.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.84 | 2022 | |
| Amgen INC. | $12.63 | 2020 | |
| Biodelivery Sciences International, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Troyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.